




National Food Institute
Technical University of Denmark



Clinical metagenomics in urinary tract infections



Frank M. Aarestrup
DTU – Food
www.genomicepidemiology.com
www.compare-europe.eu






FIG 2 Schematic representation of the workflow anticipated after adoption of whole-genome sequencing used either on cultured isolates or directly on the clinical samples, with an expected time scale.

Metagenomic sequencing directly on the samples can reduce time and improve result

Rapid Whole-Genome Sequencing for Detection and Characterization of Microorganisms Directly from Clinical Samples

Henrik Hasman,^a Dhany Saputra,^b Thomas Sicheritz-Ponten,^b Ole Lund,^b Christina Aaby Svendsen,^a Niels Friimodt-Møller,^c Frank M. Aarestrup^a

National Food Institute, Technical University of Denmark, Lyngby, Denmark^a; Systems Biology, Technical University of Denmark, Lyngby, Denmark^b; Hvidovre Hospital, Hvidovre, Denmark^c


Whole-genome sequencing (WGS) is becoming available as a routine tool for clinical microbiology. If applied directly on clinical samples, this could further reduce diagnostic times and thereby improve control and treatment. A major bottleneck is the availability of fast and reliable bioinformatic tools. This study was conducted to evaluate the applicability of WGS directly on clinical samples and to develop easy-to-use bioinformatic tools for the analysis of sequencing data. Thirty-five random urine samples from patients with suspected urinary tract infections were examined using conventional microbiology, WGS of isolated bacteria,

The study


- 35 random urinary samples
- Routine culturing
 - All isolated bacteria WGS
- Direct sequencing
 - Reads mapped to databases

Results - ID


- Cultures from 19 (pure from 17)
 - WGS improved identification
- Metagenomics from 23
 - Four culture negative (*G. vaginalis*, *L. iners*, *Prevotella*, *E. coli*/*E. faecalis*)
 - Two mixed cultures (*E. coli*, *E. coli*/*E. faecalis*)




Online bioinformatic tool



ResFinder usage, August 2012 - December 2015
Total use: 74500 runs




Distribution among countries 2015
69 different countries in total



	Phenotypic	
	Resistant	Susceptible
Predicted resistant	475	7
Predicted susceptible	16	2553

99.2% concordance

retest




	Phenotypic	
	Resistant	Susceptible
Resistant	475	7
Susceptible	0	2569

99.8% concordance

Spectinomycin in *E. coli*

Number of reads mapping to
tetracycline resistant and tetracycline susceptible
Enterococci and E. coli





Agreement to resistance


Number	Species	Phenotypic resistance	WGS predicted	Metagenomic predicted
10	E. coli	S	S	ESBL
21	E. coli	AMP, CIP, GEN, NAL	AMP, GEN, TET	AMP, GEN, TET
27	E. coli	S	S	TET

Improving the methods

Bias the data




Test data



143 isolates from Oxford University Hospital, comprising 858 phenotypic susceptibility tests, most on beta-lactams.

193 isolates from Danish pig farms, comprising 2,547 phenotypic susceptibility tests, covering a broad spectrum of antibiotic classes.



Sequence quality and resistance determination

	SRST2	ResFinder	Kmer
SE	95	94	97
SP	96	96	97
	<i>Down sampled</i>		
SE	29	17	95
SP	98	98	97

Metagenomic assignment metamerfinder

$$P(T < t_i) = 1 - e^{-\lambda_i t_i} \quad , \quad \lambda = \frac{1}{\mu_i} \quad \wedge \quad i \in (Depth; Coverage)$$

Equation 2; The exponential survival function, μ : background expectation, t : measured quality


Agreement to resistance

No	Species	Phenotypic resistance	WGS predicted	Metagenomic predicted	Metamerfinder
3	E. faecalis	TET	TET	TET	E. faecalis (TET) E. coli (S) L. crispatus (ERY)
10	E. coli	S	S	ESBL	ESBL
21	E. coli	AMP, CIP, GEN, NAL	AMP, GEN, TET	AMP, GEN, TET	AMP, GEN, TET
27	E. coli	S	S	TET	TET, SUL, AMP, STR, TMP

E. coli in Urine samples


A:
ATCC 8739 reference

SNP tree



_d = Direct sequencing on urine

_i = sequencing of isolate from urine



Why a central public repository?

Besides the language and altruistic issues





- The data comparison problem
- Allowing easy transfer between levels of access including public
- Allow access to bioinformatics for the frontline and frontline data for bioinformaticians
- Allowing for constantly improving the analytic pipelines

Establishing and improving surveillance

- Rapid sharing

- Online bioinformatic tools
 - >1,000 jobs per day
- Facilities for rapid sharing




- Natural reservoirs


- Major issues with individual samples






The Rio Convention
The Nagoya Protocol

National ethical committees







Copenhagen according to sewage



Very preliminary data

Drug use the previous year

Our vision: one system serves all



Guiding principles:

- Cross sector, cross domain, open source (not commercial)
- Interaction with the rest of the world (all inclusive)
- Data for action (actionable outputs)
- Central repository (ENA, DDJ, NCBI) (bring the tools to the data)

**There can be no real-time detection & surveillance
without real-time data sharing**